The authors regret that the affiliations for Dr A. De Toma and Dr G. Lo Russo were incorrect when the article was published. Their correct affiliation is Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. The authors would like to apologise for any inconvenience caused.
Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., et al. (2021). Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)). ESMO OPEN, 6(3), 1-1 [10.1016/j.esmoop.2021.100137].
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078))
De Giglio A.;
2021
Abstract
The authors regret that the affiliations for Dr A. De Toma and Dr G. Lo Russo were incorrect when the article was published. Their correct affiliation is Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. The authors would like to apologise for any inconvenience caused.File | Dimensione | Formato | |
---|---|---|---|
PIIS205970292100096X.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
163.96 kB
Formato
Adobe PDF
|
163.96 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.